ReviewNature reviews. Endocrinology2010
Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.
Review in Nature reviews. Endocrinology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 118 citations in OpenAlex.
- Effects of an isocaloric healthy Nordic diet on insulin sensitivity, lipid profile and inflammation markers in metabolic syndrome -- a randomized study (SYSDIET).Journal of internal medicine · 2013Trial
- Dietary Interventions for Hypertriglyceridemia.Current atherosclerosis reports · 2026Review
- Reconceptualizing Dyslipidemia: Diversity of Lipid Imbalances and Their Clinical Implications; A Narrative Review.Health science reports · 2026Article
- The Association of Remnant Cholesterol with Obstructive Sleep Apnea and Coronary Heart Disease: A Cross-Sectional Study.Vascular health and risk management · 2026Article
- Is the Commitment to LDL-C Eternal?Methodist DeBakey cardiovascular journal · 2026Review
- Current opinions on the role of apolipoprotein B in the clinical management of cardiovascular risk.Future cardiology · 2025Article
- Severe Hypertriglyceridemia in Pregnancy: Clinical Approach and Management Strategies.JCEM case reports · 2025Article
- Association between total and regional body fat measured by dual-energy X-ray absorptiometry and apolipoprotein B.Scientific reports · 2025Article
- Multi-omic integration sets the path for early prevention strategies on healthy individuals.NPJ genomic medicine · 2025Article
- Review
- Mini-Review: Immunogenic epitopes in apolipoprotein B-100 for atheroprotective immunization.Frontiers in cardiovascular medicine · 2024Review
- Applicability of Diagnostic Criteria and High Prevalence of Familial Dysbetalipoproteinemia in Russia: A Pilot Study.International journal of molecular sciences · 2023Article
- Hypertriglyceridemic hyperapoB and the development and resolution of nonalcoholic fatty liver disease: a cohort study.Journal of lipid research · 2023Article
- Management of Patients with Type V Hyperlipoproteinemia: An Uncommon Phenotype of Dyslipidemia with Chylomicronemia and Severe Hypertriglyceridemia.Journal of personalized medicine · 2022Article
- Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk.Journal of the American Heart Association · 2022Review
- Apolipoproteins in vascular biology and atherosclerotic disease.Nature reviews. Cardiology · 2022Review
- Sex-specific associations of adiposity with cardiometabolic traits in the UK: A multi-life stage cohort study with repeat metabolomics.PLoS medicine · 2022Article
- A new phenotypic classification system for dyslipidemias based on the standard lipid panel.Lipids in health and disease · 2021Article
- Sex differences in systemic metabolites at four life stages: cohort study with repeated metabolomics.BMC medicine · 2021Article
- Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia).Archives of medical science : AMS · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventionally, atherogenic dyslipidemias have been defined by elevated levels of triglyceride and/or LDL cholesterol. However, cholesterol and triglycerides are not metabolically and physically independent entities. Rather, they are constituents of the atherogenic apolipoprotein B (apoB) particles, which differ in their origin and their metabolic function. Moreover, the risk of vascular disease is not related to the plasma concentration of cholesterol or triglyceride per se, but to the number, composition and size of the apoB particles, within which the cholesterol and triglycerides are contained. After all, the entire apoB particle--rather than individual cholesterol or triglyceride molecules--enters and is trapped within the arterial wall, and this particle initiates and sustains the process that results in atherosclerosis. Accordingly, we suggest a change of name and focus from dyslipidemias to dyslipoproteinemias. Virtually all the atherogenic apoB dyslipoproteinemias can be specifically identified on the basis of plasma levels of cholesterol, triglyceride and apoB. Not only does this enable an accurate diagnosis in the individual, but the major familial dyslipoproteinemias can be identified as well. Here, we review the diagnostic algorithm for apoB dyslipoproteinemias and provide, for the first time, a treatment plan on the basis of a reduction of atherogenic lipoprotein particles rather than plasma lipids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.